Carsten Nieder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7943397/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 511-519.	0.8	351
2	L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 64-74.	0.8	236
3	Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1446-1449.	0.8	198
4	Tissue tolerance to reirradiation. Seminars in Radiation Oncology, 2000, 10, 200-209.	2.2	175
5	Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?. International Journal of Radiation Oncology Biology Physics, 2001, 50, 727-733.	0.8	170
6	Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?. International Journal of Radiation Oncology Biology Physics, 2000, 46, 297-302.	0.8	165
7	Presentation, patterns of care, and survival in patients with brain metastases. Cancer, 2011, 117, 2505-2512.	4.1	163
8	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1069-1076.	0.8	161
9	Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. International Journal of Radiation Oncology Biology Physics, 2005, 61, 851-855.	0.8	146
10	Rapid course radiation therapy vs. more standard treatment: A randomized trial for bone metastases. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1085-1089.	0.8	129
11	Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiation Oncology, 2014, 9, 155.	2.7	129
12	Tumor-related prognostic factors for remission of brain metastases after radiotherapy. International Journal of Radiation Oncology Biology Physics, 1997, 39, 25-30.	0.8	117
13	Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treatment Reviews, 2006, 32, 348-364.	7.7	109
14	Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure. Radiotherapy and Oncology, 2011, 101, 245-249.	0.6	106
15	Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. Critical Reviews in Oncology/Hematology, 2006, 60, 181-193.	4.4	97
16	11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 339-344.	0.8	97
17	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 300-305. 	1.3	94
18	Prognostic indices for brain metastases – usefulness and challenges. Radiation Oncology, 2009, 4, 10.	2.7	91

#	Article	IF	CITATIONS
19	Radiotherapy for High-Grade Gliomas. Strahlentherapie Und Onkologie, 2004, 180, 401-407.	2.0	90
20	A palliative accelerated irradiation regimen for advanced non–small-cell lung cancer VS. conventionally fractionated 60 GY: results of a randomized equivalence study. International Journal of Radiation Oncology Biology Physics, 2000, 48, 95-103.	0.8	87
21	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open, 2018, 3, e000406.	4.5	84
22	Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases. Strahlentherapie Und Onkologie, 2015, 191, 461-469.	2.0	77
23	Late Radiation Toxicity After Whole-Brain Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 573.	1.3	76
24	Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. , 1999, 86, 900-902.		74
25	Whole Brain Irradiation With Hippocampal Sparing and Dose Escalation on Multiple Brain Metastases: A Planning Study on Treatment Concepts. International Journal of Radiation Oncology Biology Physics, 2013, 85, 264-270.	0.8	72
26	Relation between local result and total dose of radiotherapy for brain metastases. International Journal of Radiation Oncology Biology Physics, 1995, 33, 349-355.	0.8	60
27	Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlentherapie Und Onkologie, 1998, 174, 275-278.	2.0	60
28	Retreatment of the spinal cord with palliative radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1288-1292.	0.8	54
29	Recursive Partitioning Analysis (RPA) Class Does Not Predict Survival in Patients with Four or More Brain Metastases. Strahlentherapie Und Onkologie, 2003, 179, 16-20.	2.0	51
30	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Critical Reviews in Oncology/Hematology, 2018, 126, 13-18.	4.4	51
31	Colorectal Cancer Metastatic to the Brain: Time Trends in Presentation and Outcome. Oncology, 2009, 76, 369-374.	1.9	50
32	Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiation Oncology, 2015, 10, 69.	2.7	49
33	The Role of Postoperative Radiotherapy after Resection of a Single Brain Metastasis. Strahlentherapie Und Onkologie, 2007, 183, 576-580.	2.0	48
34	Re-irradiation for Recurrent Primary Brain Tumors. Anticancer Research, 2016, 36, 4985-4996.	1.1	47
35	Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clinical and Experimental Metastasis, 2013, 30, 723-729.	3.3	44
36	The role of pentoxifylline as a modifier of radiation therapy. Cancer Treatment Reviews, 2005, 31, 448-455.	7.7	42

#	Article	IF	CITATIONS
37	Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. Pharmacoeconomics, 2017, 35, 1223-1236.	3.3	42
38	Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiotherapy and Oncology, 2007, 82, 301-307.	0.6	41
39	Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1337-1341.	1.1	41
40	Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer, 2010, 10, 284.	2.6	41
41	Hippocampusâ€avoidance wholeâ€brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer, 2020, 126, 2694-2703.	4.1	41
42	Prognostic scores in brain metastases from breast cancer. BMC Cancer, 2009, 9, 105.	2.6	40
43	Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiation Oncology, 2007, 2, 20.	2.7	38
44	Dose/effect relationships for brain metastases. Journal of Cancer Research and Clinical Oncology, 1998, 124, 346-350.	2.5	36
45	Treatment of unresectable glioblastoma multiforme. Anticancer Research, 2005, 25, 4605-10.	1.1	36
46	Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer. Supportive Care in Cancer, 2016, 24, 4385-4391.	2.2	35
47	Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiation Oncology, 2017, 12, 107.	2.7	35
48	Expert consensus on re-irradiation for recurrent glioma. Radiation Oncology, 2017, 12, 194.	2.7	32
49	Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer. Journal of Cancer, 2016, 7, 125-130.	2.5	31
50	Validation of the graded prognostic assessment index for patients with brain metastases. Acta Oncológica, 2009, 48, 457-459.	1.8	30
51	High-Precision Radiation Therapy with Integrated Biological Imaging and Tumor Monitoring. Strahlentherapie Und Onkologie, 2006, 182, 361-368.	2.0	29
52	Treatment of brain metastases from renal cell cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 405-410.	1.6	29
53	Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?. Radiation Oncology, 2013, 8, 85.	2.7	29
54	Oligometastatic Non-Small Cell Lung Cancer: A Significant Entity outside of Specialized Cancer Centers?. Medical Principles and Practice, 2014, 23, 526-531.	2.4	28

#	Article	IF	CITATIONS
55	Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus. Strahlentherapie Und Onkologie, 2006, 182, 179-182.	2.0	27
56	Adverse events in hospitalised cancer patients: a comparison to a general hospital population. Acta Oncológica, 2017, 56, 1218-1223.	1.8	27
57	A Review of Current and Future Treatment Strategies for Malignant Astrocytomas in Adults. Strahlentherapie Und Onkologie, 2000, 176, 251-258.	2.0	26
58	Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. Strahlentherapie Und Onkologie, 2012, 188, 692-695.	2.0	26
59	Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. Medical Science Monitor, 2012, 18, CR450-CR455.	1.1	26
60	Cervical lymph node metastases from occult squamous cell carcinoma. Current Treatment Options in Oncology, 2002, 3, 33-40.	3.0	25
61	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 129, 63-71.	2.0	25
62	Accelerated radiotherapy for brain metastases. Radiotherapy and Oncology, 1997, 45, 17-22.	0.6	24
63	Correlation between article download and citation figures for highly accessed articles from five open access oncology journals. SpringerPlus, 2013, 2, 261.	1.2	24
64	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	2.7	24
65	Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiotherapy and Oncology, 2019, 130, 121-131.	0.6	24
66	Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiation Oncology Investigations, 1999, 7, 36-41.	0.9	23
67	Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. Reviews on Recent Clinical Trials, 2007, 2, 163-168.	0.8	23
68	Resource Utilization in Patients with Brain Metastases Managed with Best Supportive Care, Radiotherapy and/or Surgical Resection: A Markov Analysis. Oncology, 2010, 78, 348-355.	1.9	22
69	A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiation Oncology, 2012, 7, 3.	2.7	22
70	Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids. Supportive Care in Cancer, 2013, 21, 2671-2678.	2.2	22
71	Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Impact of Total Radiation Dose on Survival?. Journal of Clinical Medicine Research, 2017, 9, 482-487.	1.2	22
72	Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treatment Reviews, 2003, 29, 11-19.	7.7	21

#	Article	IF	CITATIONS
73	Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma?. Journal of Cancer Research and Therapeutics, 2011, 7, 47.	0.9	21
74	Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clinical Neurology and Neurosurgery, 2016, 142, 81-86.	1.4	21
75	Radiotherapy and Chemotherapy for Myoepithelioma of the Sellar Region. Strahlentherapie Und Onkologie, 2005, 181, 260-263.	2.0	20
76	Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Research, 2003, 23, 5117-23.	1.1	20
77	Prevention of radiation-induced central nervous system toxicity: a role for amifostine?. Anticancer Research, 2004, 24, 3803-9.	1.1	20
78	Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide. Reviews on Recent Clinical Trials, 2006, 1, 43-51.	0.8	19
79	Experimental concepts for toxicity prevention and tissue restoration after central nervous system irradiation. Radiation Oncology, 2007, 2, 23.	2.7	19
80	Palliative radiotherapy during the last month of life: Predictability for referring physicians and radiation oncologists. Oncology Letters, 2015, 10, 3043-3049.	1.8	19
81	Local control and overall survival after frameless radiosurgery: A single center experience. Clinical and Translational Radiation Oncology, 2017, 7, 55-61.	1.7	19
82	Radiation myelopathy: New perspective on an old problem. Radiation Oncology Investigations, 1999, 7, 193-203.	0.9	18
83	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Review of Neurotherapeutics, 2004, 4, 691-703.	2.8	18
84	Estimating Need for Palliative External Beam Radiotherapy in Adult Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 207-211.	0.8	18
85	Contribution of adverse events to death of hospitalised patients. BMJ Open Quality, 2019, 8, e000377.	1.1	18
86	Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. Anticancer Research, 2014, 34, 877-85.	1.1	18
87	Effects of Insulin-Like Growth Factor-1 (IGF-1) and Amifostine in Spinal Cord Reirradiation. Strahlentherapie Und Onkologie, 2005, 181, 691-695.	2.0	17
88	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlentherapie Und Onkologie, 2018, 194, 365-374.	2.0	17
89	Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1257-1263.	0.8	16
90	Effects of Smoking Cessation on Hypoxia and its Potential Impact on Radiation Treatment Effects in Lung Cancer Patients. Strahlentherapie Und Onkologie, 2008, 184, 605-609.	2.0	16

#	Article	IF	CITATIONS
91	Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. International Journal of Circumpolar Health, 2015, 74, 26686.	1.2	16
92	Prospective randomized clinical studies involving reirradiation. Strahlentherapie Und Onkologie, 2016, 192, 679-686.	2.0	16
93	Preserving the legacy of reirradiation: A narrative review of historical publications. Advances in Radiation Oncology, 2017, 2, 176-182.	1.2	16
94	Second re-irradiation: a narrative review of the available clinical data. Acta Oncológica, 2018, 57, 305-310.	1.8	16
95	Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Research, 2002, 22, 1017-23.	1.1	16
96	Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. Anticancer Research, 2008, 28, 3015-7.	1.1	16
97	Potential Role of Growth Factors in Diminishing Radiation Therapy Neural Tissue Injury. Seminars in Oncology, 2005, 32, 67-70.	2.2	15
98	Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiation Oncology, 2006, 1, 19.	2.7	15
99	Postoperative treatment and prognosis of patients with resected single brain metastasis: How useful are established prognostic scores?. Clinical Neurology and Neurosurgery, 2011, 113, 98-103.	1.4	15
100	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Medical Hypotheses, 2011, 76, 410-413.	1.5	15
101	Survival Prediction Score: A Simple but Age-Dependent Method Predicting Prognosis in Patients Undergoing Palliative Radiotherapy. ISRN Oncology, 2014, 2014, 1-5.	2.1	15
102	Predicted survival in patients with brain metastases from colorectal cancer: Is a current nomogram helpful?. Clinical Neurology and Neurosurgery, 2016, 143, 107-110.	1.4	15
103	Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Medicine, 2018, 7, 2350-2359.	2.8	15
104	External Validation of the LabBM Score in Patients With Brain Metastases. Journal of Clinical Medicine Research, 2019, 11, 321-325.	1.2	15
105	Polypharmacy in Older Patients ≥70 Years Receiving Palliative Radiotherapy. Anticancer Research, 2017, 37, 795-800.	1.1	15
106	Radiotherapy-induced lung toxicity: risk factors and prevention strategies. Anticancer Research, 2003, 23, 4991-8.	1.1	15
107	Multivariate logistic analysis of dose–effect relationship and latency of radiomyelopathy after hyperfractionated and conventionally fractionated radiotherapy in animal experiments. International Journal of Radiation Oncology Biology Physics, 1998, 41, 681-688.	0.8	14
108	Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases. Medical Oncology, 2014, 31, 927.	2.5	14

#	Article	IF	CITATIONS
109	Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Research, 2014, 34, 1015-20.	1.1	14
110	Is Whole-Brain Radiotherapy Effective and Safe in Elderly Patients with Brain Metastases?. Oncology, 2007, 72, 326-329.	1.9	13
111	Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report). World Journal of Surgical Oncology, 2010, 8, 36.	1.9	13
112	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageÂl disease. Strahlentherapie Und Onkologie, 2017, 193, 515-524.	2.0	13
113	Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases. In Vivo, 2016, 30, 879-884.	1.3	13
114	The role of growth factors in central nervous system tumours. Anticancer Research, 2003, 23, 1681-6.	1.1	13
115	Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1513-1518.	0.8	12
116	Glioblastoma research 2006–2010: Pattern of citation and systematic review of highly cited articles. Clinical Neurology and Neurosurgery, 2012, 114, 1207-1210.	1.4	12
117	Towards Improved Prognostic Scores Predicting Survival in Patients with Brain Metastases: A Pilot Study of Serum Lactate Dehydrogenase Levels. Scientific World Journal, The, 2012, 2012, 1-5.	2.1	12
118	Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison. Radiation Oncology, 2015, 10, 61.	2.7	12
119	Radiotherapy for nonagenarians: the value of biological versus chronological age. Radiation Oncology, 2020, 15, 113.	2.7	12
120	Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients?. Anticancer Research, 2009, 29, 2641-4.	1.1	12
121	A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer. Anticancer Research, 2012, 32, 189-94.	1.1	12
122	Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway. International Journal of Circumpolar Health, 2012, 71, 19127.	1.2	11
123	The challenge of durable brain control in patients with brain-only metastases from breast cancer. SpringerPlus, 2015, 4, 585.	1.2	11
124	Early palliative radiation therapy in patients with newly diagnosed cancer: Reasons, clinical practice, and survival. Practical Radiation Oncology, 2015, 5, e537-e542.	2.1	11
125	Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram?. Journal of Cancer, 2017, 8, 1525-1529.	2.5	11
126	Hippocampus-Avoidance Whole-Brain Radiation Therapy Is Efficient in the Long-Term Preservation of Hippocampal Volume. Frontiers in Oncology, 2021, 11, 714709.	2.8	11

#	Article	IF	CITATIONS
127	Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Journal of Clinical Medicine Research, 2018, 10, 178-181.	1.2	11
128	Presence of Brain Metastases at Initial Diagnosis of Cancer: Patient Characteristics and Outcome. Cureus, 2019, 11, e4113.	0.5	11
129	Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles. American Journal of Cancer Research, 2013, 3, 152-8.	1.4	11
130	Survival after palliative radiotherapy in geriatric cancer patients. Anticancer Research, 2014, 34, 6641-5.	1.1	11
131	Validation of Graded Prognostic Assessment Index for Patients With Brain Metastases: In Regard to Sperduto et al. (Int J Radiat Oncol Biol Phys 2008;70:510–514). International Journal of Radiation Oncology Biology Physics, 2008, 72, 1619.	0.8	10
132	Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urology, 2010, 10, 23.	1.4	10
133	Comorbidity, Use of Common Medications, and Risk of Early Death in Patients with Localized or Locally Advanced Prostate Cancer. Scientific World Journal, The, 2011, 11, 1178-1186.	2.1	10
134	Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations. Frontiers in Oncology, 2013, 3, 176.	2.8	10
135	Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. Oncology Letters, 2016, 12, 2930-2935.	1.8	10
136	Patient-reported symptoms before palliative radiotherapy predict survival differences. Strahlentherapie Und Onkologie, 2018, 194, 533-538.	2.0	10
137	Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases. Anticancer Research, 2021, 41, 1471-1474.	1.1	10
138	New clinical data on human spinal cord re-irradiation tolerance. Strahlentherapie Und Onkologie, 2021, 197, 463-473.	2.0	10
139	Palliative Radiotherapy During the Last Month of Life: Have COVID-19 Recommendations Led to Reduced Utilization?. In Vivo, 2021, 35, 649-652.	1.3	10
140	Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. Journal of Clinical Medicine Research, 2017, 9, 183-187.	1.2	10
141	Hypofractionated Stereotactic Radiotherapy for Malignant Glioma: A Phase I/II Study. Journal of Radiosurgery, 1999, 2, 107-111.	0.1	9
142	Evaluation of insulin-like growth factor-1 for prevention of radiation-induced spinal cord damage. Growth Factors, 2005, 23, 15-18.	1.7	9
143	Impact of comorbidity on survival after palliative radiotherapy. Strahlentherapie Und Onkologie, 2014, 190, 1149-1153.	2.0	9
144	External Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer. Clinical Lung Cancer, 2017, 18, e297-e301.	2.6	9

#	Article	IF	CITATIONS
145	Risk Factors for Local Relapse and Inferior Disease-free Survival After Breast-conserving Management of Breast Cancer: Recursive Partitioning Analysis of 2161 Patients. Clinical Breast Cancer, 2019, 19, 58-62.	2.4	9
146	Long-term survival results after treatment for oligometastatic brain disease. Reports of Practical Oncology and Radiotherapy, 2020, 25, 307-311.	0.6	9
147	Does Marital Status Influence Levels of Anxiety and Depression Before Palliative Radiotherapy?. In Vivo, 2018, 32, 327-330.	1.3	9
148	Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer. Anticancer Research, 2014, 34, 7255-61.	1.1	9
149	Palliative Radiotherapy in Cancer Patients with Increased Serum C-Reactive Protein Level. In Vivo, 2016, 30, 581-6.	1.3	9
150	Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. , 1999, 85, 251-252.		8
151	Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases. Medical Oncology, 2012, 29, 2664-2668.	2.5	8
152	Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research. Tumor Biology, 2015, 36, 6471-6476.	1.8	8
153	Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Medical Oncology, 2017, 34, 149.	2.5	8
154	External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors. Clinical and Translational Radiation Oncology, 2019, 16, 15-20.	1.7	8
155	External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment. Oncology Research and Treatment, 2020, 43, 221-227.	1.2	8
156	The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy. Reports of Practical Oncology and Radiotherapy, 2021, 26, 740-746.	0.6	8
157	Dose–Response Relationships for Radiotherapy of Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 584-588.	1.3	8
158	Early palliative care in patients with metastatic non-small cell lung cancer. Annals of Palliative Medicine, 2012, 1, 84-6.	1.2	8
159	A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate. Case Reports in Oncological Medicine, 2012, 2012, 1-3.	0.3	7
160	Brain Metastases Research 1990–2010: Pattern of Citation and Systematic Review of Highly Cited Articles. Scientific World Journal, The, 2012, 2012, 1-9.	2.1	7
161	Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement. In Vivo, 2019, 33, 229-232.	1.3	7
162	Second re-irradiation: A delicate balance between safety and efficacy. Physica Medica, 2019, 58, 155-158.	0.7	7

#	Article	IF	CITATIONS
163	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. Radiotherapy and Oncology, 2021, 159, 17-20.	0.6	7
164	Second Re-irradiation of Brain Metastases: A Review of Studies Involving Stereotactic Radiosurgery. Cureus, 2018, 10, e3712.	0.5	7
165	Patient-reported Symptom Burden, Rate of Completion of Palliative Radiotherapy and 30-day Mortality in Two Groups of Cancer Patients Managed With or Without Additional Care by a Multidisciplinary Palliative Care Team. Anticancer Research, 2018, 38, 2271-2275.	1.1	7
166	Dose to the intracranial arteries in stereotactic and intensity-modulated radiotherapy for skull base tumors. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1055-1059.	0.8	6
167	Acceleration of Normal-Tissue Damage Expression by Early Stimulation of Cell Proliferation in Rat Spinal Cord. Strahlentherapie Und Onkologie, 2006, 182, 680-684.	2.0	6
168	Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?. Radiation Oncology, 2008, 3, 2.	2.7	6
169	Validation of New Prognostic and Predictive Scores by Sequential Testing Approach. Strahlentherapie Und Onkologie, 2010, 186, 169-173.	2.0	6
170	Ipilimumab in patients with melanoma and brain metastases. Lancet Oncology, The, 2012, 13, e277.	10.7	6
171	Contribution of case reports to glioblastoma research: Systematic review and analysis of pattern of citation. British Journal of Neurosurgery, 2012, 26, 809-812.	0.8	6
172	Development of a Score Predicting Survival after Palliative Reirradiation. Journal of Oncology, 2014, 2014, 1-7.	1.3	6
173	PET-CT in the sub-arctic region of Norway 2010–2013. At the edge of what is possible?. BMC Medical Imaging, 2015, 15, 36.	2.7	6
174	Extracranial oral cavity metastasis from glioblastoma multiforme: A case report. Molecular and Clinical Oncology, 2016, 5, 437-439.	1.0	6
175	Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians). Technical Innovations and Patient Support in Radiation Oncology, 2017, 1, 8-12.	1.9	6
176	Contemporary radiooncological management of bone metastases from breast cancer: factors associated with prescription of different fractionation regimens (short or long course) in a rural part of North Norway with long travel distance. International Journal of Circumpolar Health, 2017, 76. 1270080.	1.2	6
177	Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?. International Journal of Circumpolar Health, 2019, 78, 1620086.	1.2	6
178	Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer. Radiation Oncology, 2020, 15, 91.	2.7	6
179	Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). Radiation Oncology, 2020, 15, 35.	2.7	6
180	Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol. Anticancer Research, 2007, 27, 2993-6.	1.1	6

#	Article	IF	CITATIONS
181	Disease presentation and outcome in young patients (<40 years) with brain metastases from malignant melanoma. Anticancer Research, 2008, 28, 1325-7.	1.1	6
182	A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis. Anticancer Research, 2010, 30, 977-9.	1.1	6
183	30-day mortality in patients treated for brain metastases: extracranial causes dominate. Radiation Oncology, 2022, 17, 92.	2.7	6
184	Disease Presentation and Treatment Outcome in Very Young Patients with Brain Metastases from Lung Cancer. Onkologie, 2008, 31, 305-308.	0.8	5
185	Brain metastases in patients under 50Âyears of age: retrospective analysis. Clinical and Experimental Metastasis, 2012, 29, 949-956.	3.3	5
186	A Case of Recurrent Breast Cancer with Solitary Metastasis to the Urinary Bladder. Case Reports in Oncological Medicine, 2014, 2014, 1-3.	0.3	5
187	A Four-Tiered Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer. Cancer Investigation, 2018, 36, 59-65.	1.3	5
188	Provider decision regret—aÂuseful method for analysis of palliative thoracic re-irradiation for lung cancer?. Strahlentherapie Und Onkologie, 2020, 196, 315-324.	2.0	5
189	Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region. Cureus, 2020, 12, e7030.	0.5	5
190	Expansion of the LabBM Score. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 53-57.	1.3	5
191	Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation. Anticancer Research, 2016, 36, 355-60.	1.1	5
192	Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.3	4
193	Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients – Long term data on toxicity and biochemical control. Reports of Practical Oncology and Radiotherapy, 2019, 24, 315-321.	0.6	4
194	Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer. In Vivo, 2019, 33, 465-468.	1.3	4
195	Recursive Partitioning Analysis of Systemic Therapy after Radiotherapy in Patients with Brain Metastases. Oncology Research and Treatment, 2021, 44, 1-6.	1.2	4
196	Symptom Burden in Patients Treated With Palliative Radiotherapy Before and During the COVID-19 Pandemic. Anticancer Research, 2021, 41, 1971-1974.	1.1	4
197	Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?. Anticancer Research, 2021, 41, 355-358.	1.1	4
198	Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?. Anticancer Research, 2018, 38, 901-904.	1.1	4

3

#	Article	IF	CITATIONS
199	Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement. In Vivo, 2022, 36, 801-805.	1.3	4
200	Brain Metastases in Renal Cell Cancer: Diagnostic and Therapeutic Aspects. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 632-634.	1.3	3
201	Re-Irradiation for Recurrent Head and Neck Cancer: in Regard to Lee etÂal. (Int J Radiat Oncol Biol Phys) Tj ETQq1	1 0.78431 0.8	L4 ₃ rgBT /Ovi
202	Two New Prognostic Indices for Brain Metastases – Where Do We Go from Here?. Strahlentherapie Und Onkologie, 2008, 184, 488-489.	2.0	3
203	Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?. Journal of Oncology, 2008, 2008, 1-5.	1.3	3
204	Presentation and outcome in cancer patients with extensive spread to the brain. BMC Research Notes, 2009, 2, 247.	1.4	3
205	Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates. Medical Hypotheses, 2012, 78, 420-422.	1.5	3
206	Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns. Oncology Letters, 2014, 8, 972-976.	1.8	3
207	Palliative radiotherapy (PRT) during the last month of life: A constant sorrow even in a dedicated PRT facility with research focus on this endpoint. Radiotherapy and Oncology, 2015, 115, 284.	0.6	3
208	The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy. Molecular and Clinical Oncology, 2017, 6, 811-816.	1.0	3
209	Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases. Medical Oncology, 2018, 35, 46.	2.5	3
210	Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2019, 39, 335-340.	1.1	3
211	Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases. In Vivo, 2019, 33, 173-176.	1.3	3
212	Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy. Anticancer Research, 2020, 40, 977-981.	1.1	3
213	Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases. In Vivo, 2020, 34, 675-678.	1.3	3
214	Symptom Burden in Patients With Reduced Performance Status at the Start of Palliative Radiotherapy. In Vivo, 2020, 34, 735-738.	1.3	3
215	Hyperfractionated and acceleratedâ€hyperfractionated radiotherapy for glioblastoma multiforme. Radiation Oncology Investigations, 1999, 7, 36-41.	0.9	3

Early and Late Treatment-Induced Toxicity. , 2006, , 317-332.

#	Article	IF	CITATIONS
217	Contribution of Case Reports to Brain Metastases Research: Systematic Review and Analysis of Pattern of Citation. PLoS ONE, 2012, 7, e34300.	2.5	3
218	Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models. Anticancer Research, 2018, 38, 1705-1709.	1.1	3
219	A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?. Annals of Translational Medicine, 2015, 3, 148.	1.7	3
220	Evaluation of late neurologic adverse events in patients with brain metastases from non-small cell lung cancer. Anticancer Research, 2007, 27, 1701-4.	1.1	3
221	Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. Anticancer Research, 2007, 27, 2353-7.	1.1	3
222	Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy. Anticancer Research, 2022, 42, 1477-1480.	1.1	3
223	Palliative radiotherapy in patients with metastatic non-small cell lung cancer. Annals of Palliative Medicine, 2013, 2, 51-3.	1.2	3
224	What Approach will Lead to Cure of Glioblastoma Multiforme?: In Regard to Barani etÂal. (Int J Radiat) Tj ETQq0 C International Journal of Radiation Oncology Biology Physics, 2007, 69, 640-641.	0 rgBT /C 0.8	overlock 10 T 2
225	Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?. Clinical and Translational Oncology, 2011, 13, 885-888.	2.4	2
226	Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?. ISRN Oncology, 2013, 2013, 1-4.	2.1	2
227	Palliative Radiotherapy with or without Additional Care by a Multidisciplinary Palliative Care Team: A Retrospective Comparison. ISRN Oncology, 2014, 2014, 1-6.	2.1	2
228	Repeat palliative radiotherapy for painful bone metastases. Lancet Oncology, The, 2014, 15, 126-128.	10.7	2
229	In Regard to Alcorn etÂal. International Journal of Radiation Oncology Biology Physics, 2021, 110, 612-614.	0.8	2
230	Early High-Grade Thoracic Toxicity After Palliative Radiotherapy for Non-Small Cell Lung Cancer. Cureus, 2021, 13, e12494.	0.5	2
231	How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?. In Vivo, 2018, 32, 331-336.	1.3	2
232	Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome. Cureus, 2020, 12, e6553.	0.5	2
233	Independent External Validation of a Score Predicting Survival After Radiotherapy for Bone Metastases and Expansion to Patients Treated With Single Fraction Radiotherapy. Journal of Clinical Medicine Research, 2020, 12, 90-99.	1.2	2
234	Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer. Anticancer Research, 2011, 31, 1735-9.	1.1	2

#	Article	IF	CITATIONS
235	Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting. Scandinavian Journal of Urology, 2022, 56, 114-118.	1.0	2
236	Effects of radiotherapy and chemotherapy on sensory deficits from spinal cord damage. Acta Oncológica, 2005, 44, 412-414.	1.8	1
237	Response Monitoring by Positron Emission Tomography during Radiotherapy of a Squamous Cell Skin Carcinoma. Oncology Research and Treatment, 2005, 28, 505-507.	1.2	1
238	An uncommon presentation and course of metastatic malignant melanoma: a case report. Journal of Medical Case Reports, 2007, 1, 151.	0.8	1
239	A Thought-Provoking Retrospective Study on Survival and Toxicity After Reirradiation for Recurrent High-Grade Gliomas. Journal of Clinical Oncology, 2011, 29, e121-e121.	1.6	1
240	Fractionation Concepts. Medical Radiology, 2016, , 17-34.	0.1	1
241	Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors. Oncology Letters, 2016, 11, 1138-1142.	1.8	1
242	Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study. Radiation Oncology, 2020, 15, 111.	2.7	1
243	Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting. Scandinavian Journal of Urology, 2020, 54, 110-114.	1.0	1
244	Neurological Death After Radiotherapy for Brain Metastases: Role of the LabBM Score. Anticancer Research, 2021, 41, 341-345.	1.1	1
245	Applications in Malignant Brain Tumors. , 2006, , 165-186.		1
246	Quantitative Cell Kill of Radio- and Chemotherapy. Medical Radiology, 2009, , 169-190.	0.1	1
247	Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer. Cureus, 2017, 9, e1412.	0.5	1
248	Frequency and Prognostic Impact of Consistently Low Edmonton Symptom Assessment System Score in the Patients Treated with Palliative Radiotherapy. Cureus, 2018, 10, e2032.	0.5	1
249	Second Re-irradiation: Clinical Examples of Worthwhile Treatment. Cureus, 2018, 10, e2813.	0.5	1
250	Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	1
251	Clinical effectiveness of radiotherapy for non-Hodgkin's lymphoma: a summary. Cancer Treatment Reviews, 2004, 30, 221-224.	7.7	0
252	Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report. Cases Journal, 2008, 1, 195.	0.4	0

#	Article	IF	CITATIONS
253	Normal Tissue Tolerance to Reirradiation. Medical Radiology, 2010, , 1-12.	0.1	0
254	Fractionation Concepts. Medical Radiology, 2010, , 13-26.	0.1	0
255	Brain Metastases. Medical Radiology, 2010, , 209-223.	0.1	0
256	Re-irradiation. , 2013, , 739-748.		0
257	Radioimmunotherapy (RIT). , 2013, , 729-729.		0
258	Scientific impact of studies published in temporarily available radiation oncology journals: a citation analysis. SpringerPlus, 2015, 4, 93.	1.2	0
259	Normal Tissue Tolerance to Reirradiation. Medical Radiology, 2016, , 1-15.	0.1	0
260	Brain Metastases. Medical Radiology, 2016, , 337-356.	0.1	0
261	Radiation Therapy in Brain Metastasis of Solid Tumors: A Challenge for the Future. , 2018, , 1-16.		0
262	Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?. International Journal of Circumpolar Health, 2020, 79, 1742520.	1.2	0
263	Symptom Burden in Patients With Oligometastases at the Start of Palliative Radiotherapy. Anticancer Research, 2020, 40, 1551-1554.	1.1	Ο
264	Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival. Journal of Clinical Medicine Research, 2021, 13, 177-183.	1.2	0
265	An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer. In Vivo, 2021, 35, 955-958.	1.3	0
266	Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery. In Vivo, 2021, 35, 1569-1572.	1.3	0
267	Radiate Once More. International Journal of Radiation Oncology Biology Physics, 2021, 109, 314-315.	0.8	0
268	Mechanisms of Treatment Resistance: Molecular and Clinical Examples for Radio- and Chemotherapy. Medical Radiology, 2009, , 243-250.	0.1	0
269	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. Medical Radiology, 2009, , 335-346.	0.1	0
270	Randomized Controlled Clinical Trials in Radiation Therapy: Patterns of Publication in the Most Frequently Cited Studies. Medical Science Review, 0, 2, 104-110.	0.0	0

#	Article	IF	CITATIONS
271	A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine Research, 2017, 9, 281-288.	1.2	0
272	Levels of Anxiety and Depression Before Palliative Reirradiation Are Comparable to Those Before First Palliative Radiotherapy. Cureus, 2018, 10, e2519.	0.5	0
273	LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy. Cureus, 2020, 12, e7633.	0.5	0
274	A Case of Five-Year Survival After Combined-Modality Treatment for Non-Small Cell Lung Cancer With Intraspinal Metastasis. Cureus, 2022, 14, e20960.	0.5	0
275	Dual Use of the METSSS Model Predicting Survival After Palliative Radiotherapy: An Exploratory Analysis. Cureus, 2022, 14, e21223.	0.5	0
276	Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort. Anticancer Research, 2022, 42, 923-928.	1.1	0
277	Shortened Palliative Radiotherapy Results in a Lower Rate of Treatment During the Last Month of Life. Cureus, 2022, 14, e21617.	0.5	Ο
278	Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. Anticancer Research, 2007, 27, 183-7.	1.1	0
279	Disease presentation and outcome in very young patients with brain metastases from breast cancer. Tumori, 2008, 94, 691-3.	1.1	Ο
280	Palliative non-small cell lung cancer treatment and end-of-life care stratified by sex and childlessness: an important interplay in unmarried patients?. Supportive Care in Cancer, 2022, , 1.	2.2	0